

TALL STATURE PANEL WITH GENOME WIDE CNV ANALYSIS DG-3.9.0 (40 GENES)

| <i>Gene</i> | <i>Twist X2 covered >10x</i> | <i>Twist X2 covered >20x</i> | <i>WGS covered >10x</i> | <i>WGS covered >20x</i> | <i>Associated Phenotype description and OMIM disease ID</i> |
|-------------|---------------------------------|---------------------------------|----------------------------|----------------------------|--|
| ABCC9 | 100.0% | 100.0% | 100.0% | 98.4% | Cardiomyopathy, dilated, 10, 608569;Hypertrichotic osteochondrodysplasia (Cantu syndrome), 239850;?Atrial fibrillation, familial, 12, 614050;Intellectual disability and myopathy syndrome, 619719 |
| AKT2 | 100.0% | 100.0% | 100.0% | 98.6% | Diabetes mellitus, type II, 125853;Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 |
| APC2 | 100.0% | 100.0% | 100.0% | 96.8% | Cortical dysplasia, complex, with other brain malformations 10, 618677;Intellectual developmental disorder, autosomal recessive 74, 617169 |
| BRWD3 | 100.0% | 99.7% | 97.7% | 71.0% | Intellectual developmental disorder, X-linked 93, 300659 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| CBS | 100.0% | 100.0% | 100.0% | 99.5% | Thrombosis, hyperhomocysteinemic, 236200;Homocystinuria, B6-responsive and nonresponsive types, 236200 |
| CDKN1C | 100.0% | 100.0% | 100.0% | 92.1% | IMAGE syndrome, 614732;Beckwith-Wiedemann syndrome, 130650 |
| CHD8 | 100.0% | 100.0% | 100.0% | 98.4% | Intellectual developmental disorder with autism and macrocephaly, 615032 |
| CYP19A1 | 100.0% | 99.9% | 100.0% | 98.8% | Aromatase deficiency, 613546;Aromatase excess syndrome, 139300 |
| DIS3L2 | 100.0% | 100.0% | 100.0% | 98.7% | Perlman syndrome, 267000 |
| DNMT3A | 100.0% | 100.0% | 100.0% | 99.4% | Tatton-Brown-Rahman syndrome, 615879;Acute myeloid leukemia, somatic, 601626;Heyn-Sproul-Jackson syndrome, 618724 |
| EED | 100.0% | 100.0% | 99.9% | 95.0% | Cohen-Gibson syndrome, 617561 |
| EZH2 | 100.0% | 100.0% | 100.0% | 99.0% | Weaver syndrome, 277590 |

| | | | | | |
|------|--------|--------|--------|-------|---|
| FBN1 | 100.0% | 100.0% | 100.0% | 99.1% | Geleophysic dysplasia 2, 614185;Weill-Marchesani syndrome 2, dominant, 608328;Ectopia lentis, familial, 129600;MASS syndrome, 604308;Marfan lipodystrophy syndrome, 616914;Acromicric dysplasia, 102370;Marfan syndrome, 154700;Stiff skin syndrome, 184900 |
| FBN2 | 100.0% | 100.0% | 100.0% | 99.4% | Macular degeneration, early-onset, 616118;Contractural arachnodactyly, congenital, 121050 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| FGFR3 | 100.0% | 100.0% | 100.0% | 99.8% | Muenke syndrome, 602849;SADDAN, 616482;Hypochondroplasia, 146000;Thanatophoric dysplasia, type II, 187601;Nevus, epidermal, somatic, 162900;CATSHL syndrome, 610474;Thanatophoric dysplasia, type I, 187600;Spermatocytic seminoma, somatic, 273300;Bladder cancer, somatic, 109800;LADD syndrome 2, 620192;Achondroplasia, 100800;Cervical cancer, somatic, 603956;Colorectal cancer, somatic, 114500;Crouzon syndrome with acanthosis nigricans, 612247 |
| FIBP | 100.0% | 100.0% | 100.0% | 98.7% | Thauvin-Robinet-Faivre syndrome, 617107 |
| GPC3 | 99.6% | 98.9% | 97.7% | 68.3% | Wilms tumor, somatic, 194070;Simpson-Golabi-Behmel syndrome, type 1, 312870 |
| GPR101 | 100.0% | 100.0% | 97.9% | 69.4% | Pituitary adenoma 2, GH-secreting, 300943 |
| H19 | | | | | |

| | | | | | |
|----------|--------|--------|--------|-------|---|
| HERC1 | 100.0% | 100.0% | 100.0% | 99.2% | Macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 |
| IGF1R | 100.0% | 100.0% | 100.0% | 99.1% | Insulin-like growth factor I, resistance to, 270450 |
| KCNQ1OT1 | | | | | Beckwith-Wiedemann syndrome, 130650 |
| MED12 | 100.0% | 99.8% | 97.5% | 69.0% | Lujan-Fryns syndrome, 309520;Ohdo syndrome, X-linked, 300895;Hardikar syndrome, 301068;Opitz-Kaveggia syndrome, 305450 |
| MTOR | 100.0% | 100.0% | 100.0% | 99.3% | Focal cortical dysplasia, type II, somatic, 607341;Smith-Kingsmore syndrome, 616638 |
| NFIX | 100.0% | 99.7% | 99.7% | 96.9% | Marshall-Smith syndrome, 602535;Malan syndrome, 614753 |
| NKAP | 100.0% | 100.0% | 96.4% | 67.3% | Intellectual developmental disorder, X-linked syndromic, Hackman-Di Donato type, 301039 |
| NPR2 | 100.0% | 100.0% | 100.0% | 99.1% | Epiphyseal chondrodysplasia, Miura type, 615923;Short stature with nonspecific skeletal abnormalities, 616255;Acromesomelic dysplasia 1, Maroteaux type, 602875 |

| | | | | | |
|--------|--------|--------|--------|-------|--|
| NPR3 | 100.0% | 100.0% | 100.0% | 98.7% | Boudin-Mortier syndrome, 619543 |
| NSD1 | 100.0% | 100.0% | 100.0% | 98.6% | Sotos syndrome, 117550 |
| PDGFRB | 100.0% | 100.0% | 100.0% | 99.2% | Premature aging syndrome, Penttinen type, 601812;Kosaki overgrowth syndrome, 616592;Myofibromatosis, infantile, 1, 228550;Basal ganglia calcification, idiopathic, 4, 615007;Myeloproliferative disorder with eosinophilia, 131440 |
| RNF125 | 100.0% | 100.0% | 100.0% | 99.0% | Tenorio syndrome, 616260 |
| RNF135 | 100.0% | 100.0% | 100.0% | 98.8% | |
| SETD2 | 100.0% | 100.0% | 100.0% | 97.9% | Luscan-Lumish syndrome, 616831;Intellectual developmental disorder, autosomal dominant 70, 620157;Rabin-Pappas syndrome, 620155 |
| SMAD2 | 100.0% | 100.0% | 100.0% | 99.0% | Loeys-Dietz syndrome 6, 619656;Congenital heart defects, multiple types, 8, with or without heterotaxy, 619657 |
| SMAD3 | 100.0% | 100.0% | 99.9% | 96.8% | Loeys-Dietz syndrome 3, 613795 |
| SUZ12 | 100.0% | 100.0% | 100.0% | 94.8% | Imagawa-Matsumoto syndrome, 618786 |

| | | | | | |
|--------|--------|--------|--------|-------|--|
| TGFB2 | 100.0% | 100.0% | 100.0% | 98.4% | Loeys-Dietz syndrome 4, 614816 |
| TGFB3 | 100.0% | 100.0% | 100.0% | 99.5% | Arrhythmogenic right ventricular dysplasia 1, 107970;Loeys-Dietz syndrome 5, 615582 |
| TGFBR1 | 100.0% | 100.0% | 100.0% | 96.7% | {Multiple self-healing squamous epithelioma, susceptibility to}, 132800;Loeys-Dietz syndrome 1, 609192 |
| TGFBR2 | 100.0% | 100.0% | 100.0% | 98.5% | Loeys-Dietz syndrome 2, 610168;Colorectal cancer, hereditary nonpolyposis, type 6, 614331;Esophageal cancer, somatic, 133239 |

Gene symbols used follow HGCN guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST X2 Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using TWIST X2 chemistry.

TWIST X2 Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using TWIST X2 chemistry.

srWGS GRCh38 Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38.

srWGS GRCh38 Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : March 17th, 2023.

This list is accurate for panel version DG 3.9.0

[EAS.GenProductCoverage.pdf.footer.ad01](#)